Istituto Superiore Di Sanita

Other

Novartis Vaccines & Diagnostics, Gmbh

Università Degli Studi Di Firenze

Novadigm Therapeutics, Inc.

Pevion Biotech Ag

Pevion Biotech Ltd.

Torosantucci, Antonella

Cassone, Antonio

Antonio Cassone

Flavia De Bernardis

Luciano Polonelli

Antonella Torosantucci

Rinaldo Zurbriggen

Silvia Rasi

Steven Grant

Enrico Garaci

Antonio Guarna

Haiqun Liu

Luisa Bracci

Andrea Trabocchi

Neri Paolo

Luisa Lozzi

The present invention relates to an isolated truncated form of the secretory aspartyl proteinase 2, as well as to nucleic acid molecules encoding same. The present invention also relates to a composition comprising an isolated truncated form of the secretory aspartyl proteinase 2, as well as to nucleic acid molecules encoding same.

Truncated secretory aspartyl proteinase 2

Anti-glucan antibodies have been found to be protective against systemic fungal infection with, but the protective efficacy can be inhibited by blocking antibodies. The invention provides an immunogenic composition comprising a glucan and a pharmaceutically acceptable carrier, characterized in that, when administered to a mammalian recipient, the composition elicits protective anti-glucan antibodies but does not elicit antibodies which inhibit the protective efficacy of the anti-glucan antibodies. The glucan may be presented on the surface of a protease-treated microbial cell or may be presented as a protein-glucan conjugate. The glucan may be substituted by a glucan mimotope, a peptidomimetic of a glucan mimotope, or nucleic acid encoding a mimotope. Anti-glucan-antibodies show broad spectrum microbicidal activity. &#x3b2;-glucans are preferred, particularly those containing one or more &#x3b2;-1,6 linkages.

Glucan-based vaccines

The present invention refers to 3-aza-bicyclo [3.2.1] octane derivatives of general formula (I) their preparation, use and pharmaceutical compositions useful in the treatment of pathologies associated with microbial pathogens expressing aspartylprotease activity.

Bicyclic peptidomimetic inhibitors of aspartyl-proteases for the treatment of infectious diseases

Anti-&#x3b2;-1,3-glucan antibodies have been found to be protective against systemic fungal infection with. The present invention provides monoclonal antibodies that bind to &#x3b2;-1,3-glucan, hybridoma cell lines producing the antibodies, compositions comprising the antibodies and methods of using such antibodies for treatment of microbial infections, particularly againstandinfections. The antibodies of the present invention are not specific for &#x3b2;-1,6-glucan.

Protective anti-glucan antibodies with preference for &#x3b2;-1,3-glucans

Anti-&#x3b2;-1,3-glucan antibodies have been found to be protective against systemic fungal infection with. The present invention provides monoclonal antibodies that bind to &#x3b2;-1,3-glucan, hybridoma cell lines producing the antibodies, compositions comprising the antibodies and methods of using such antibodies for treatment of microbial infections, particularly againstandinfections. The antibodies of the present invention are not specific for (&#x3b2;-1,6-glucan.

This invention relates to domain antibodies. In particular, it relates to domain antibodies (dAbs) that recognize virulence traits ofspp. and confer passive protection against candidiasis.

[object Object]

Protective anti-glucan antibodies with preference for &#x3b2;-1,3- glucans

Anti-idiotypic antibodies which recognise the idiotope of an antibody specific for a yeast killer toxin possess microbicidal activity. Fragments (e.g. decapeptides) of these anti-idiotypic antibodies, particularly those comprising CDR residues, also show microbicidal activity, as do peptides having 5 the same sequence but composed of D-amino acids, or including amino acid substitutions. Peptidomimetics of these microbicidal polypeptides are also provided. Antiviral activity is also seen.

Toxin-related antibodies with antimicrobial and antiviral activity

Growing community of inventors

Rome, Italy

Antonio Cassone